The main objective of the randomized MyPeBS study is to compare the current organized screening system - based on age alone (except for women identified as very high risk) - with a new strategy of Screening offering a type and frequency of examinations based on each woman’s level of risk. This risk score is calculated from various personal data for each woman: clinical data (age, family history of cancer, age of the first period, etc.), radiological (breast density), and genetic (analysis of a score of polymorphisms associated with the risk of breast cancer, via a salivary test).
The study, promoted by Unicancer and coordinated by Dr. Suzette Delaloge, medical oncologist, head of the Breast Pathology Committee at Gustave Roussy, plans to recruit 85,000 women aged 40 to 70 in 5 countries (France, United Kingdom, Italy, Belgium, Israel), with a follow-up period of 4 years. Half of women will follow standard screening and half will be screened based on their risk assessment.
The main objective of MyPeBS is to demonstrate whether personalized screening is at least as effective as standard screening in preventing the development of stage 2 and higher breast cancers. The secondary objectives are to assess whether such screening avoids more stage 2 and higher cancers, if it has fewer drawbacks than standard screening, and is more acceptable to women than the latter.
If this study is positive, it could change the practice of breast cancer screening in Europe.
Predilife is one of the partners in this major project funded by the European Union, in charge of assessing the individual risk of breast cancer in the MyPeBS study.
For more information: www.mypebs.eu